Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

NCT06056830 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

383

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Prostatic Neoplasms

Interventions

DRUG: 64Cu-SAR-bisPSMA

Sponsor

Clarity Pharmaceuticals Ltd